Literature DB >> 27342081

Aberrant adenosine A2A receptor signaling contributes to neurodegeneration and cognitive impairments in a mouse model of synucleinopathy.

Qidi Hu1, Xiangpeng Ren2, Ya Liu1, Zhihui Li3, Liping Zhang3, Xingjun Chen1, Chaoxiang He1, Jiang-Fan Chen4.   

Abstract

Synucleinopathy is characterized by abnormal accumulation of misfolded α-synuclein (α-Syn)-positive cytoplasmic inclusions and by neurodegeneration and cognitive impairments, but the pathogenesis mechanism of synucleinopathy remains to be defined. Using a transmission model of synucleinopathy by intracerebral injection of preformed A53T α-Syn fibrils, we investigated whether aberrant adenosine A2A receptor (A2AR) signaling contributed to pathogenesis of synucleinopathy. We demonstrated that intra-hippocampal injection of preformed mutant α-Syn fibrils triggered a striking and selective induction of A2AR expression which was closely co-localized with pSer129 α-Syn-rich inclusions in neurons and glial cells of hippocampus. Importantly, by abolishing aberrant A2AR signaling triggered by mutant α-Syn, genetic deletion of A2ARs blunted a cascade of pathological events leading to synucleinopathy, including pSer129 α-Syn-rich and p62-positive aggregates, NF-κB activation and astrogliosis, apoptotic neuronal cell death and working memory deficits without affecting motor activity. These findings define α-Syn-triggered aberrant A2AR signaling as a critical pathogenesis mechanism of synucleinopathy with dual controls of cognition and neurodegeneration by modulating α-Syn aggregates. Thus, aberrant A2AR signaling represents a useful biomarker as well as a therapeutic target of synucleinopathy.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adenosine A(2A) receptor; Hippocampus; Synucleinopathy; α-Synuclein

Mesh:

Substances:

Year:  2016        PMID: 27342081     DOI: 10.1016/j.expneurol.2016.05.040

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  18 in total

Review 1.  Purinergic Receptors in Basal Ganglia Diseases: Shared Molecular Mechanisms between Huntington's and Parkinson's Disease.

Authors:  Talita Glaser; Roberta Andrejew; Ágatha Oliveira-Giacomelli; Deidiane Elisa Ribeiro; Lucas Bonfim Marques; Qing Ye; Wen-Jing Ren; Alexey Semyanov; Peter Illes; Yong Tang; Henning Ulrich
Journal:  Neurosci Bull       Date:  2020-10-07       Impact factor: 5.203

2.  Critical appraisal of pathology transmission in the α-synuclein fibril model of Lewy body disorders.

Authors:  Negin Nouraei; Daniel M Mason; Kristin M Miner; Michael A Carcella; Tarun N Bhatia; Benjamin K Dumm; Dishaben Soni; David A Johnson; Kelvin C Luk; Rehana K Leak
Journal:  Exp Neurol       Date:  2017-10-19       Impact factor: 5.330

Review 3.  Do caffeine and more selective adenosine A2A receptor antagonists protect against dopaminergic neurodegeneration in Parkinson's disease?

Authors:  Jiang-Fan Chen; Michael A Schwarzschild
Journal:  Parkinsonism Relat Disord       Date:  2020-12-19       Impact factor: 4.891

4.  Understanding the Role of Adenosine A2AR Heteroreceptor Complexes in Neurodegeneration and Neuroinflammation.

Authors:  Dasiel O Borroto-Escuela; Sonja Hinz; Gemma Navarro; Rafael Franco; Christa E Müller; Kjell Fuxe
Journal:  Front Neurosci       Date:  2018-02-06       Impact factor: 4.677

Review 5.  Adenosine heteroreceptor complexes in the basal ganglia are implicated in Parkinson's disease and its treatment.

Authors:  Dasiel O Borroto-Escuela; Kjell Fuxe
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

6.  P2X7 receptor-pannexin 1 interaction mediates extracellular alpha-synuclein-induced ATP release in neuroblastoma SH-SY5Y cells.

Authors:  Anna Wilkaniec; Magdalena Gąssowska; Grzegorz A Czapski; Magdalena Cieślik; Grzegorz Sulkowski; Agata Adamczyk
Journal:  Purinergic Signal       Date:  2017-05-17       Impact factor: 3.765

Review 7.  Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy.

Authors:  Ágatha Oliveira-Giacomelli; Yahaira Naaldijk; Laura Sardá-Arroyo; Maria C B Gonçalves; Juliana Corrêa-Velloso; Micheli M Pillat; Héllio D N de Souza; Henning Ulrich
Journal:  Front Pharmacol       Date:  2018-04-10       Impact factor: 5.810

8.  Chronic Caffeine Treatment Protects Against α-Synucleinopathy by Reestablishing Autophagy Activity in the Mouse Striatum.

Authors:  Yanan Luan; Xiangpeng Ren; Wu Zheng; Zhenhai Zeng; Yingzi Guo; Zhidong Hou; Wei Guo; Xingjun Chen; Fei Li; Jiang-Fan Chen
Journal:  Front Neurosci       Date:  2018-05-02       Impact factor: 4.677

9.  Adenosine A2A receptors facilitate synaptic NMDA currents in CA1 pyramidal neurons.

Authors:  Francisco M Mouro; Diogo M Rombo; Raquel B Dias; Joaquim A Ribeiro; Ana M Sebastião
Journal:  Br J Pharmacol       Date:  2018-10-17       Impact factor: 8.739

Review 10.  Purinergic Signalling in Parkinson's Disease: A Multi-target System to Combat Neurodegeneration.

Authors:  Adrián Tóth; Zsófia Antal; Dániel Bereczki; Beáta Sperlágh
Journal:  Neurochem Res       Date:  2019-05-04       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.